Elizabeta Popa, MD
Hematology · New York, NYNPI 1104845205
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 33 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by AstraZeneca at 41.9% of the total. That places this record below the midpoint for hematology clinicians in NY, where the typical reported total is $619.
Across 33 payments — averaging $22.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$312
- Novartis$86
- AbbVie$71
- Amgen$51
- Ipsen Biopharmaceuticals, Inc$45
- Merck$38
- plus $143 from 6 others
Across 6 payments — averaging $9219.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Seagen Inc.$41K
- E.r. Squibb & Sons, L.L.C.$14K
- Eli Lilly$1K
What the payments were for
- Food & beverage$745100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 14 | $312 |
| Novartis | 3 | $86 |
| AbbVie | 4 | $71 |
| Amgen | 2 | $51 |
| Ipsen Biopharmaceuticals, Inc | 2 | $45 |
| Merck | 2 | $38 |
| Taiho Oncology, Inc. | 1 | $35 |
| Immunocore Limited | 1 | $30 |
| Regeneron Healthcare Solutions, Inc. | 1 | $28 |
| Spectrum Pharmaceuticals Inc. | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $15 |
How this compares
$745 in reported general payments places this provider in the 50th percentile of 157 hematology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 20 | $13,563 |
| XareltoRivaroxaban | 20 | $10,871 |
| CholestyramineCholestyramine (With Sugar) | 12 | $1,949 |
| Dexamethasone | 12 | $358 |
| Levothyroxine Sodium | 19 | $322 |
| Ondansetron OdtOndansetron | 40 | $313 |
| Oxycodone Hcl | 17 | $160 |
| Gabapentin | 13 | $127 |
| Hydrocortisone | 12 | $58 |
Paid to pharmacies, not to this prescriber.
Other hematology in New York
- Barry CollerNew York$7.9M
- Allyson OceanNew York$1.4M
- Ahmed SawasNew York$618K
- Jeffrey ZwickerNew York$561K
- Dan DouerNew York$477K
- Ran ReshefNew York$468K
- Faith DaviesNew York$307K
- Michael MauroNew York$229K
- Richard FurmanNew York$208K
- Ann JakubowskiNew York$123K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.